13 completed, 5 unknown, 2 terminated. 10 Phase 3, 7 Phase 2, 3 Phase 1, 3 Phase 4, 2 Not applicable.
Follow Lenograstim: new trials by email Literature Review of Lenograstim trials Research Report on Lenograstim
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuous Versus Bolus Administration of G-CSF in Children With Cancer G-CSF administration (bolus injection versus intravenous infusion) - Pediatric Cancer, Neutropenia | Phase 4 | Unknown | Chang Gung Memorial Hospital | 20 | 2023-11-23 | 2024-09-19 |
| Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim), Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim) - Localized Breast Cancer | Not applicable | Completed | Centre Georges Francois Leclerc | 97 | 2022-09-02 | 2026-02-19 |
| Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF) lenograstim - Neutropenia | Not applicable | Unknown | DERSHENG SUN | 155 | 2018-02-19 | 2018-04-13 |
| Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF) - Prostate Cancer Metastatic | Phase 3 | Completed | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 196 | 2017-05-05 | 2022-05-12 |
| Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte) Lenograstim - Healthy Volunteers | Phase 1 | Terminated | CellProthera | 40 | 2015-09-10 | 2026-10-16 |
| Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Azacitadine, Fludarabine, Cytarabine - Acute Myeloid Leukemia | Phase 3 | Completed | PETHEMA Foundation | 289 | 2014-10-01 | 2020-04-06 |
| A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) Melphalan, Lenograstim - Castrate Resistant Prostate Cancer | Phase 2 / Phase 3 | Terminated | Barts & The London NHS Trust | 29 | 2013-01-01 | 2023-04-19 |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine Cytarabine, Idarubicin, Etoposide - Acute Myeloid Leukemia (AML) | Phase 2 | Completed | University of Ulm | 277 | 2010-11-01 | 2020-12-31 |
| Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy granulocyte colony stimulating factor (GCSF), bone marrow mononuclear cells - Dilated Cardiomyopathy | Phase 2 | Completed | Barts & The London NHS Trust | 60 | 2010-08-01 | 2013-11-15 |
| A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen LENOGRASTIM (GRANOGYTE 34) - Neoplasms (no Otherwise Specified) | Phase 4 | Completed | Sanofi | 403 | 2010-03-01 | 2012-10-05 |
| Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction Lenograstim (GRANOCYTE)=GCSF, Sitagliptin (Januvia), Sodium Chloride (NaCl) 0.9 % - Acute Myocardial Infarction | Phase 2 / Phase 3 | Completed | Ludwig-Maximilians - University of Munich | 174 | 2008-03-01 | 2022-08-25 |
| Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer Docetaxel, Epirubicin, Cyclophosphamide - Breast Cancer | Phase 3 | Completed | Hellenic Oncology Research Group | 650 | 2007-10-01 | 2014-05-14 |
| Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors filgrastim, lenograstim, pegfilgrastim - Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor | Phase 1 / Phase 2 | Unknown | University of Southampton | 23 | 2006-11-01 | 2013-01-23 |
| Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL Bortezomib, Cyclophosphamide, Doxorubicin - Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell | Phase 1 / Phase 2 | Completed | Asan Medical Center | 49 | 2006-09-01 | 2013-03-15 |
| Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Rituximab, Ciclofosfamide, Doxorubicina - Diffuse Large B-Cell Lymphoma, IPI≥2 | Phase 3 | Unknown | Fondazione Italiana Linfomi - ETS | 399 | 2006-01-01 | 2011-02-15 |
| Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma filgrastim, lenograstim - G-CSF, Multiple Myeloma, Febrile Episode, Filgrastim, Leograstim | Phase 3 | Unknown | University of Pisa | 180 | 2004-12-01 | 2009-07-03 |
| Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer Docetaxel, Trastuzumab, Epirubicin - Breast Cancer | Phase 3 | Completed | Hellenic Oncology Research Group | 489 | 2004-10-01 | 2015-03-04 |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer Docetaxel, Paclitaxel, Epirubicin - Breast Cancer | Phase 3 | Completed | Hellenic Oncology Research Group | 478 | 2004-08-01 | 2008-01-21 |
| Bone Marrow Stem Cell Mobilisation Therapy for Acute Myocardial Infarction (AMI)(REVIVAL-2) G-CSF Granulocyte-Colony Stimulating Factor, Placebo - Myocardial Infarction | Phase 4 | Completed | Deutsches Herzzentrum Muenchen | 114 | 2004-02-01 | 2007-11-26 |
| Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy lenograstim - Hodgkin's Disease, Non-Hodgkin Lymphomas | Phase 2 / Phase 3 | Completed | WiSP Wissenschaftlicher Service Pharma GmbH | 169 | 2003-05-01 | 2010-03-11 |
Breast Neoplasms (4) · Leukemia, Myeloid, Acute (2) · Lymphoma, Large B-Cell, Diffuse (2) · Multiple Myeloma (2) · Myocardial Infarction (2) · Neoplasms (2) · Neutropenia (2) · Cardiomyopathy, Dilated (1) · Central Nervous System Neoplasms (1) · Endodermal Sinus Tumor (1) · Hodgkin Disease (1) · Lymphoma, B-Cell (1) · Ovarian Neoplasms (1) · Seminoma (1) · Testicular Germ Cell Tumor (1)
Hellenic Oncology Research Group (3) · Barts & The London NHS Trust (2) · Asan Medical Center (1) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (1) · CellProthera (1) · Centre Georges Francois Leclerc (1) · Chang Gung Memorial Hospital (1) · DERSHENG SUN (1) · Deutsches Herzzentrum Muenchen (1) · Fondazione Italiana Linfomi - ETS (1) · Ludwig-Maximilians - University of Munich (1) · PETHEMA Foundation (1) · Sanofi (1) · University of Pisa (1) · University of Southampton (1)
Germany (4) · France (3) · Greece (3) · United Kingdom (3) · South Korea (2) · Austria (1) · Italy (1) · South Africa (1) · Spain (1) · Taiwan (1)
Dimitris Mavrudis, MD (3) · Adnan Kastrati, MD (1) · Albert Schomig, MD (1) · Anthony Mathur, MD FRCP FESC (1) · Catherine Mutter, MD (1) · Cheolwon Suh, M.D.,Ph.D. (1) · G. Mead, MD (1) · Jonathan Shamash, MD FRCP (1) · Pau Montesinos, Dr (1) · Richard F Schlenk, MD (1) · Umberto Vitolo, MD (1) · Wolfgang M Franz, Prof. Dr. (1) · Yoon Ho Ko (1)
PMID 12084168, PMID 16096770, PMID 16507801, PMID 21163927, PMID 26709136, PMID 27502729, PMID 28419427, PMID 28668386, PMID 32817282, PMID 33463373, PMID 34070172, PMID 34208815, PMID 34494505, PMID 35785754, PMID 37883073, PMID 37885041, PMID 42020286
2009 (1)